Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Terminated 4Withdrawn 3Recruiting 3Active not recruiting 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 111Carcinoma, Non-Small-Cell Lung 102Prostatic Neoplasms 66Multiple Myeloma 64Neoplasm Metastasis 63Colorectal Neoplasms 63Neoplasms 59Lung Neoplasms 51Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 40Lymphoma 40Leukemia, Lymphocytic, Chronic, B-Cell 36Pancreatic Neoplasms 34Melanoma 34Head and Neck Neoplasms 26Glioblastoma 26Rectal Neoplasms 25Ovarian Neoplasms 25Lymphoma, Large B-Cell, Diffuse 25Leukemia 24Brain Neoplasms 24Squamous Cell Carcinoma of Head and Neck 23Hematologic Neoplasms 23Carcinoma, Renal Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Myelodysplastic Syndromes 20Colonic Neoplasms 20Triple Negative Breast Neoplasms 19Lymphoma, Non-Hodgkin 19

Interventions

AZD 6244 2Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Neurofibroma, Plexiform × Clear all
NCT05825365 2023-08-14

PROTECT

AstraZeneca

Phase 2 Withdrawn
CNS

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03688568 2021-02-12

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Indiana University

Phase 2 Withdrawn
CNS

Neurofibroma, Plexiform

NCT03109301 2019-04-05

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
CNS

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡